In the latest episode of Blood Cancer Talks, Michael Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Center in Melbourne, Australia, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; to discuss bispecific antibodies across lymphomas.
Dr. Dickinson and the hosts circled several research articles into their conversation, including a phase I/II study of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL); a phase II trial of mosunetuzumab in relapsed or refractory follicular lymphoma; and a phase I trial of odronextamab in relapsed or refractory B-cell non-hodgkin lymphoma (NHL).
This podcast originally appeared on Blood Cancer Talks.